CCL2 and hepatocellular carcinoma: Together, results from Figure 3e suggest that Sorafenib alone has either little effect or some increase on p‐Src/Jak2/p‐STAT3/CCL2/Bcl2 signals and addition of ASC‐J9® enhances Sorafenib efficacy to suppress HCC cell invasion and proliferation via suppressing p‐Src/Jak2/p‐STAT3/CCL2/Bcl2 signals in the three different HCC cell lines.